First Novel-Food Authorisations Near
The FSA is consulting on the first proposed CBD food authorisations, with initial approvals targeted for around autumn 2026 — per the regulator. Here's what the last mile of a long process actually involves.
By Staff, CBD Wire
Years after the UK told CBD companies to join the novel-foods queue, the front of the queue is finally in sight. The Food Standards Agency has been consulting on the first proposed authorisations of CBD food products, and — per the regulator — the first approvals are targeted for around autumn 2026. As of this writing, that is a target, not a promise; but it is the most concrete date the process has yet produced.
What a consultation means here
Authorisation is the last stretch of a long road. A CBD product sold as food in the UK needs a novel-food authorisation; the applications that would grant one have been working through safety assessment for years. A consultation at this stage is the standard step before the final decision: the proposed authorisations are put on the record, interested parties respond, and ministers sign off on the outcome. It is the regulatory equivalent of a pharmacist reading the label back to you before handing over the bag — deliberate, and by design.
If the autumn target holds, the products covered by those first applications would move from “tolerated while the paperwork is assessed” to “authorised” — a status no CBD food in the UK has yet held.
What it changes, and what it doesn’t
Authorisation attaches to specific products under specific applications, not to CBD as a category. The FSA’s public list — the register of CBD products linked to credible applications and allowed to remain on sale in the meantime — stays relevant for everything not yet at the front of the queue, which is most of the market.
Two things it does not do. It is not a medicines approval: an authorised CBD food is still a food. And it is not a quality guarantee for the shelf as a whole — a first tranche of authorisations tells you which applicants finished the course, nothing more.
What buyers should watch
No urgency is required. Nothing comes off the shelf because something else got authorised. But once the first approvals land, “is this product covered by an authorisation, an application, or neither?” becomes a fair question to put to any brand — and the honest ones will have a crisp answer. We would expect authorised status to appear on labels and marketing quickly, because it will be the rarest claim in the category.
We’ll report the outcome when the regulator does. Until then: the target is autumn 2026, the source is the FSA, and both of those sentences are doing exactly as much work as they appear to be.